R&D at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's R&D?
- Viking Therapeutics (VKTX) reported R&D of $150.15M in Q1 2026.
- How has Viking Therapeutics's R&D changed year-over-year?
- Viking Therapeutics's R&D increased by 262.8% year-over-year, from $41.39M to $150.15M.
- What is the long-term trend for Viking Therapeutics's R&D?
- Over 4 years (2021 to 2025), Viking Therapeutics's R&D has grown at a 66.4% compound annual growth rate (CAGR), from $44.98M to $344.96M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.